{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(1)"],"submitter":["Simon AG"],"funding":["Universitätsklinikum Köln"],"pubmed_abstract":["Background
The prognosis of esophageal adenocarcinoma (EAC) and gastric adenocarcinoma (GAC) remains poor, and new therapeutic approaches are urgently needed. Claudin 6 (CLDN6) is an oncofetal antigen that is largely absent in healthy tissues and upregulated in several cancers, making it a promising therapeutical target. In this study, the expression of CLDN6 was assessed in an large Caucasian EAC and GAC cohort.Methods
RNA-Seq data from 89 EACs and 371 GACs were obtained from The Cancer Genome Atlas project and EAC/GAC cases were stratified by CLDN6 mRNA expression based on a survival-associated cutoff. For groups with CLDN6 expression above or below this cutoff, differential gene expression analyses were performed using DESeq, and dysregulated biological pathways were ide"],"journal":["Journal of translational medicine"],"pagination":["552"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10436499"],"repository":["biostudies-literature"],"pubmed_title":["The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis."],"pmcid":["PMC10436499"],"pubmed_authors":["Bruns CJ","Lyu SI","Sahin U","Schroeder W","Tureci O","Simon AG","Laible M","Woll S","Fahrig L","Gebauer F","Zander T","Buettner R","Quaas A","Alakus H"],"additional_accession":[]},"is_claimable":false,"name":"The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.","description":"Background
The prognosis of esophageal adenocarcinoma (EAC) and gastric adenocarcinoma (GAC) remains poor, and new therapeutic approaches are urgently needed. Claudin 6 (CLDN6) is an oncofetal antigen that is largely absent in healthy tissues and upregulated in several cancers, making it a promising therapeutical target. In this study, the expression of CLDN6 was assessed in an large Caucasian EAC and GAC cohort.Methods
RNA-Seq data from 89 EACs and 371 GACs were obtained from The Cancer Genome Atlas project and EAC/GAC cases were stratified by CLDN6 mRNA expression based on a survival-associated cutoff. For groups with CLDN6 expression above or below this cutoff, differential gene expression analyses were performed using DESeq, and dysregulated biological pathways were ide","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2025-05-29T19:15:36.613Z","creation":"2024-11-05T19:25:18.718Z"},"accession":"S-EPMC10436499","cross_references":{"pubmed":["37592303"],"doi":["10.1186/s12967-023-04433-8"]}}